淡江大學覺生紀念圖書館 (TKU Library)
進階搜尋


  查詢圖書館館藏目錄
系統識別號 U0002-3107200819052200
中文論文名稱 3,3'-二吲哚甲烷抑制神經膠原致癌基因表現和轉移特性之研究
英文論文名稱 Suppression of HER2/neu expression and its metastasis by 3,3'-Diindolylmethane
校院名稱 淡江大學
系所名稱(中) 生命科學研究所碩士班
系所名稱(英) Graduate Institute of Life Sciences
學年度 96
學期 2
出版年 97
研究生中文姓名 施伊珊
研究生英文姓名 I-Shan Shih
學號 695180090
學位類別 碩士
語文別 中文
口試日期 2008-06-21
論文頁數 89頁
口試委員 指導教授-莊子超
委員-王文奇
委員-高銘欽
中文關鍵字 神經膠原致癌基因  轉移  3,3'-二吲哚甲烷 
英文關鍵字 HER2/neu  DIM  Metastasis 
學科別分類 學科別醫學與生命科學生物學
中文摘要 在人類乳癌和其它的癌症病患中約有 30~40% 肇因於神經膠原致癌基因大放大或過度表現。3,3'-二吲哚甲烷 (DIM) 為吲哚三甲醇 (I3C) 在酸性條件下所形成的雙聚體, 和 I3C 比起來,DIM 具有較穩定且較好的抗癌效果。
從最近的文獻得之 3,3'-二吲哚甲烷對於不同的癌細胞有抗增生和促進細胞凋亡的功能。在本研究中,我們首先證實 3,3'-二吲哚甲烷可抑制神經膠原致癌基因的表現。再者,更發現 3,3'-二吲哚甲烷對於神經膠原致癌基因過度表現的癌細胞,不僅能有效抑制癌細胞的存活率及降低內生性p185HER2/neu的表現,也可抑制因神經膠原致癌基因所引發的細胞癌變和轉移能力。
這些結果證實3,3'-二吲哚甲烷可做為對抗神經膠原致癌基因的標靶抗癌藥物。
關鍵字:神經膠原致癌基因、3,3'-二吲哚甲烷、轉移
英文摘要 HER2/neu oncogene is known to be amplified and/or over-expressed in approximately 30-40% of human breast cancers and many other cancers. And, 3,3’-Diindolylmethane (DIM) is a dimer of indole-3-carbinol (I3C) that is formed under acidic conditions and unlike I3C is more stable with higher anti-cancer effects. Previous studies have shown the antiproliferative and proapoptotic effects of DIM in several cancer cells. In the present study, we demonstrated for the first time that DIM suppresses the HER2/neu oncogene expression. Furthermore, we also found DIM could inhibit the survival rate and downregulate the endogenous production of p185HER2/neu of HER2/neu-overexpressing cancer cells, as well as suppress the HER2/neu-mediated transformation and metastatic potential. These data suggest that DIM may act as a HER2/neu-targeting anticancer drug.
論文目次 正文目錄
第一章 緒論 1
第一節 研究動機和目的 1
第二節 神經膠原致癌基因概論 3
一、簡介 3
二、神經膠原致癌基因和癌症 6
三、神經膠原致癌基因的訊息傳導 7
四、抑制神經膠原致癌基因表現之癌症治療研究 9
第三節 3,3'-二吲哚甲烷概論 12
一、簡介 12
二、3,3'-二吲哚甲烷(DIM)和藥理的關聯性 12
三、3,3'-二吲哚甲烷(DIM)對細胞的影響 14
第二章 材料與方法 16
第一節 實驗材料和方法 16
一、3,3'-二吲哚甲烷的配製 16
二、冷凍細胞之解凍 17
三、細胞繼代與保存 19
四、冷凍細胞 21
五、細胞計數及存活測試 24
六、3,3'-二吲哚甲烷(DIM)對癌細胞株之細胞型態的影響 26
七、細胞生長速率分析 ( MTT Assay) 26
八、西方墨點法 (Western blotting) 29
九、Scratch-Wound Assay 33
十、細胞移動性分析 (Cell Motility Assay) 34
十一、酵素圖譜活性分析 (Zymography) 36
十二、軟膠測試(Soft agar assay) 37
十三、啟動子活性測定(Luciferase assay and β-galactosidase assay) 39
十四、統計分析 41
第二節 主要儀器設備 42
第三章 結果 44
第一節 3,3'-二吲哚甲烷對p185HER2/neu 過表現細胞在增生有較佳的抑制效果 44
第二節 3,3'-二吲哚甲烷(DIM)抑制神經膠原致癌基因蛋白的表現 45
第三節 3,3'-二吲哚甲烷影響訊息傳遞途徑 47
第四節 3,3'-二吲哚甲烷抑制高表現 p185HER2/neu 癌細胞之轉移能力 47
第四章 討論 50
第五章 結論 53
第六章 參考文獻 54


圖目錄
圖1、3,3'-二吲哚甲烷對於人類卵巢癌SKOV3細胞株外觀型態上之影響 69
圖2(A)、3,3'-二吲哚甲烷對於1% FBS下抑制p185HER2/neu 過表現細胞株生長之影響 71
圖2(B)、3,3'-二吲哚甲烷主要於1% FBS下抑制p185HER2/neu 過表現細胞株生長 72
圖3、3,3'-二吲哚甲烷抑制細胞株的錨定能力(Anchorage-independent) 73
圖4、3,3'-二吲哚甲烷對於p185HER2/neu蛋白表現量之影響 74
圖5(A)、3,3'-二吲哚甲烷對p185HER2/neu蛋白分解途徑和啟動子活性之影響 75
圖5(B)、3,3'-二吲哚甲烷對p185HER2/neu蛋白分解途徑和啟動子活性之影響 76
圖6、3,3'-二吲哚甲烷對於p185HER2/neu下游之p-ERK1/2和p-p38訊息傳遞途徑之影響 77
圖7(A)、3,3'-二吲哚甲烷透過抑制p185HER2/neu而抑制轉移能力(一) 78
圖7(B)、3,3'-二吲哚甲烷透過抑制p185HER2/neu而抑制轉移能力(二) 79
圖7(C)、3,3'-二吲哚甲烷透過抑制p185HER2/neu而抑制轉移能力(三) 80


附表目錄
附表1、飲食預防試劑調控的蛋白質。(Manson et al., 2007) 81
附表2、細胞株基本資料 82
附表3、西方墨點法常用之抗體資料 83
附表 4、化學藥品及試劑(chemicals and reagents) 84


附錄目錄
附錄1、細胞培養使用之緩衝液 86
附錄2、西方墨點法使用之試劑溶液 87
附錄3、貝他半乳糖苷酶分析使用之緩衝液 89

參考文獻 Abdelrahim, M., Newman, K., Vanderlaag, K., Samudio, I. & Safe, S. (2006) 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27(4), 717-28.
Aggarwal, B.B. (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6(3), 203-8.
Anderton, M.J., Jukes, R., Lamb, J.H., Manson, M.M., Gescher, A., Steward, W.P. & Williams, M.L. (2003) Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 787(2), 281-91.
Anderton, M.J., Manson, M.M., Verschoyle, R.D., Gescher, A., Lamb, J.H., Farmer, P.B., Steward, W.P. & Williams, M.L. (2004) Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 10(15), 5233-41.
Atnip, K.D., Mahan, J.T. & Donaldson, D.J. (1987) Role of carbohydrates in cell-substrate interactions during newt epidermal cell migration. J Exp Zool 243(3), 461-71.
Bankfalvi, A., Simon, R., Brandt, B., Burger, H., Vollmer, I., Dockhorn-Dworniczak, B., Lelle, R.J. & Boecker, W. (2000) Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 37(5), 411-9.
Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13), 2825-31.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C. & Norton, L. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3), 737-44.
Bellacosa, A., Kumar, C.C., Di Cristofano, A. & Testa, J.R. (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94, 29-86.
Bhuiyan, M.M., Li, Y., Banerjee, S., Ahmed, F., Wang, Z., Ali, S. & Sarkar, F.H. (2006) Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66(20), 10064-72.
Bradlow, H.L., Michnovicz, J., Telang, N.T. & Osborne, M.P. (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12(9), 1571-4.
Busse, D., Doughty, R.S. & Arteaga, C.L. (2000) HER-2/neu (erbB-2) and the cell cycle. Semin Oncol 27(6 Suppl 11), 3-8; discussion 92-100.
Chen, Y.L., Law, P.Y. & Loh, H.H. (2005) Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 5(6), 575-89.
Cheng, J.Q., Lindsley, C.W., Cheng, G.Z., Yang, H. & Nicosia, S.V. (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24(50), 7482-92.
Chinni, S.R. & Sarkar, F.H. (2002) Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8(4), 1228-36.
Chuang, T.C., Lee, Y.J., Liu, J.Y., Lin, Y.S., Li, J.W., Wang, V., Law, S.L. & Kao, M.C. (2003) EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem Biophys Res Commun 307(3), 653-9.
Chuang, T.C., Liu, J.Y., Lin, C.T., Tang, Y.T., Yeh, M.H., Chang, S.C., Li, J.W. & Kao, M.C. (2007) Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy. FEBS Lett 581(23), 4443-9.
Chuang, T.C., Way, T.D., Lin, Y.S., Lee, Y.C., Law, S.L. & Kao, M.C. (2002a) The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett 532(1-2), 135-42.
Chuang, T.C., Yu, Y.H., Lin, Y.S., Wang, S.S. & Kao, M.C. (2002b) The N-terminal domain of SV40 large T antigen represses the HER2/neu-mediated transformation and metastatic potential in breast cancers. FEBS Lett 511(1-3), 46-50.
Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U. & et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730), 1132-9.
Cram, E.J., Liu, B.D., Bjeldanes, L.F. & Firestone, G.L. (2001) Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem 276(25), 22332-40.
Davidson, B., Konstantinovsky, S., Kleinberg, L., Nguyen, M.T., Bassarova, A., Kvalheim, G., Nesland, J.M. & Reich, R. (2006) The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 102(3), 453-61.
De Kruif, C.A., Marsman, J.W., Venekamp, J.C., Falke, H.E., Noordhoek, J., Blaauboer, B.J. & Wortelboer, H.M. (1991) Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact 80(3), 303-15.
Deshane, J., Siegal, G.P., Alvarez, R.D., Wang, M.H., Feng, M., Cabrera, G., Liu, T., Kay, M. & Curiel, D.T. (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96(6), 2980-9.
Firestone, G.L. & Bjeldanes, L.F. (2003) Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 133(7 Suppl), 2448S-2455S.
Frydoonfar, H.R., McGrath, D.R. & Spigelman, A.D. (2003) The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. ANZ J Surg 73(3), 154-6.
Garikapaty, V.P., Ashok, B.T., Tadi, K., Mittelman, A. & Tiwari, R.K. (2006) 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 340(2), 718-25.
Giannios, J. & Ioannidou-Mouzaka, L. (1997) Molecular aspects of breast and ovarian cancer. Eur J Gynaecol Oncol 18(5), 387-93.
Grose, K.R. & Bjeldanes, L.F. (1992) Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 5(2), 188-93.
Grubbs, C.J., Steele, V.E., Casebolt, T., Juliana, M.M., Eto, I., Whitaker, L.M., Dragnev, K.H., Kelloff, G.J. & Lubet, R.L. (1995) Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15(3), 709-16.
Half, E., Broaddus, R., Danenberg, K.D., Danenberg, P.V., Ayers, G.D. & Sinicrope, F.A. (2004) HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108(4), 540-8.
He, Y.H., Friesen, M.D., Ruch, R.J. & Schut, H.A. (2000) Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytochrome P450 in female F344 rats. Food Chem Toxicol 38(1), 15-23.
Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. & Mills, G.B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12), 988-1004.
Hirashima, N., Takahashi, W., Yoshii, S., Yamane, T. & Ooi, A. (2001) Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 14(6), 556-62.
Hong, C., Firestone, G.L. & Bjeldanes, L.F. (2002a) Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol 63(6), 1085-97.
Hong, C., Kim, H.A., Firestone, G.L. & Bjeldanes, L.F. (2002b) 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 23(8), 1297-305.
Hopman, A.H., Ramaekers, F.C., Raap, A.K., Beck, J.L., Devilee, P., van der Ploeg, M. & Vooijs, G.P. (1988) In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 89(4), 307-16.
Hortobagyi, G.N., Hung, M.C. & Lopez-Berestein, G. (1998) A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 9(12), 1775-98.
Howells, L.M., Gallacher-Horley, B., Houghton, C.E., Manson, M.M. & Hudson, E.A. (2002) Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther 1(13), 1161-72.
Hung, M.C. & Lau, Y.K. (1999) Basic science of HER-2/neu: a review. Semin Oncol 26(4 Suppl 12), 51-9.
Huston, J.S., McCartney, J., Tai, M.S., Mottola-Hartshorn, C., Jin, D., Warren, F., Keck, P. & Oppermann, H. (1993) Medical applications of single-chain antibodies. Int Rev Immunol 10(2-3), 195-217.
Jin, L., Qi, M., Chen, D.Z., Anderson, A., Yang, G.Y., Arbeit, J.M. & Auborn, K.J. (1999) Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 59(16), 3991-7.
Kao, M.C., Liu, G.Y., Chuang, T.C., Lin, Y.S., Wuu, J.A. & Law, S.L. (1998) The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene 16(4), 547-54.
Kay, E.W., Mulcahy, H., Walsh, C.B., Leader, M. & O'Donoghue, D. (1994) Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 25(5), 455-61.
Kim, D., Cheng, G.Z., Lindsley, C.W., Yang, H. & Cheng, J.Q. (2005) Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 6(12), 1250-8.
King, C.R., Kraus, M.H., Williams, L.T., Merlino, G.T., Pastan, I.H. & Aaronson, S.A. (1985) Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs. Nucleic Acids Res 13(23), 8477-86.
Kojima, T., Tanaka, T. & Mori, H. (1994) Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 54(6), 1446-9.
Kong, D., Li, Y., Wang, Z., Banerjee, S. & Sarkar, F.H. (2007) Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67(7), 3310-9.
Kraus, M.H., Issing, W., Miki, T., Popescu, N.C. & Aaronson, S.A. (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 86(23), 9193-7.
Kumamoto, H., Yamauchi, K., Yoshida, M. & Ooya, K. (2003) Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 32(2), 114-20.
Li, Y., Li, X. & Sarkar, F.H. (2003) Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133(4), 1011-9.
Li, Y., Wang, Z., Kong, D., Murthy, S., Dou, Q.P., Sheng, S., Reddy, G.P. & Sarkar, F.H. (2007) Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282(29), 21542-50.
Lian, J.P., Word, B., Taylor, S., Hammons, G.J. & Lyn-Cook, B.D. (2004) Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 24(1), 133-7.
Manson, M.M., Foreman, B.E., Howells, L.M. & Moiseeva, E.P. (2007) Determining the efficacy of dietary phytochemicals in cancer prevention. Biochem Soc Trans 35(Pt 5), 1358-63.
McGuire, K.P., Ngoubilly, N., Neavyn, M. & Lanza-Jacoby, S. (2006) 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 132(2), 208-13.
Meng, Q., Goldberg, I.D., Rosen, E.M. & Fan, S. (2000a) Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 63(2), 147-52.
Meng, Q., Qi, M., Chen, D.Z., Yuan, R., Goldberg, I.D., Rosen, E.M., Auborn, K. & Fan, S. (2000b) Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J Mol Med 78(3), 155-65.
Nachshon-Kedmi, M., Yannai, S. & Fares, F.A. (2004) Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. Br J Cancer 91(7), 1358-63.
Nachshon-Kedmi, M., Yannai, S., Haj, A. & Fares, F.A. (2003) Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41(6), 745-52.
Nagai, M.A., Pacheco, M.M., Oshima, C.T. & Brentani, M.M. (1993) c-erbB-2 DNA amplification and mRNA expression in human primary breast tumors and its relationship to other prognostic factors. Cancer Biother 8(1), 29-35.
Naik, R., Nixon, S., Lopes, A., Godfrey, K., Hatem, M.H. & Monaghan, J.M. (2006) A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 16(2), 786-90.
O'Hagan, R.C. & Hassell, J.A. (1998) The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 16(3), 301-10.
Oganesian, A., Hendricks, J.D. & Williams, D.E. (1997) Long term dietary indole-3-carbinol inhibits diethylnitrosamine-initiated hepatocarcinogenesis in the infant mouse model. Cancer Lett 118(1), 87-94.
Olayioye, M.A., Neve, R.M., Lane, H.A. & Hynes, N.E. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19(13), 3159-67.
Ou, C.C., Hsu, S.C., Hsieh, Y.H., Tsou, W.L., Chuang, T.C., Liu, J.Y. & Kao, M.C. (2008) Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 29(2), 299-306.
P, O.c., Rhys-Evans, P.H., Archer, D.J. & Eccles, S.A. (2002) C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38(1), 73-80.
Padhy, L.C., Shih, C., Cowing, D., Finkelstein, R. & Weinberg, R.A. (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28(4), 865-71.
Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D., Baughman, S.A., Twaddell, T., Glaspy, J.A. & Slamon, D.J. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8), 2659-71.
Plowman, G.D., Culouscou, J.M., Whitney, G.S., Green, J.M., Carlton, G.W., Foy, L., Neubauer, M.G. & Shoyab, M. (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A 90(5), 1746-50.
Popescu, N.C., King, C.R. & Kraus, M.H. (1989) Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4(3), 362-6.
Rahman, K.M., Ali, S., Aboukameel, A., Sarkar, S.H., Wang, Z., Philip, P.A., Sakr, W.A. & Raz, A. (2007) Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6(10), 2757-65.
Rahman, K.M., Sarkar, F.H., Banerjee, S., Wang, Z., Liao, D.J., Hong, X. & Sarkar, N.H. (2006a) Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 5(11), 2747-56.
Rahman, K.W., Li, Y., Wang, Z., Sarkar, S.H. & Sarkar, F.H. (2006b) Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 66(9), 4952-60.
Rahman, K.W. & Sarkar, F.H. (2005) Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65(1), 364-71.
Reed, G.A., Arneson, D.W., Putnam, W.C., Smith, H.J., Gray, J.C., Sullivan, D.K., Mayo, M.S., Crowell, J.A. & Hurwitz, A. (2006) Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev 15(12), 2477-81.
Reed, G.A., Peterson, K.S., Smith, H.J., Gray, J.C., Sullivan, D.K., Mayo, M.S., Crowell, J.A. & Hurwitz, A. (2005) A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14(8), 1953-60.
Savinainen, K.J., Saramaki, O.R., Linja, M.J., Bratt, O., Tammela, T.L., Isola, J.J. & Visakorpi, T. (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 160(1), 339-45.
Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I. & Weinberg, R.A. (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312(5994), 513-6.
Shepard, H.M., Lewis, G.D., Sarup, J.C., Fendly, B.M., Maneval, D., Mordenti, J., Figari, I., Kotts, C.E., Palladino, M.A., Jr., Ullrich, A. & et al. (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11(3), 117-27.
Shih, C., Padhy, L.C., Murray, M. & Weinberg, R.A. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290(5803), 261-4.
Stresser, D.M., Williams, D.E., Griffin, D.A. & Bailey, G.S. (1995) Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 23(9), 965-75.
Takada, Y., Andreeff, M. & Aggarwal, B.B. (2005) Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106(2), 641-9.
Takehana, T., Kunitomo, K., Kono, K., Kitahara, F., Iizuka, H., Matsumoto, Y., Fujino, M.A. & Ooi, A. (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98(6), 833-7.
Tan, M., Yao, J. & Yu, D. (1997) Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57(6), 1199-205.
Tokumaru, Y., Fujii, M., Otani, Y., Kameyama, K., Imanishi, Y., Igarashi, N. & Kanzaki, J. (2000) Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: studies of clinical samples and in vitro cell lines co-cultured with fibroblasts. Cancer Lett 150(1), 15-21.
Tsai, C.M., Levitzki, A., Wu, L.H., Chang, K.T., Cheng, C.C., Gazit, A. & Perng, R.P. (1996) Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 56(5), 1068-74.
Way, T.D., Kao, M.C. & Lin, J.K. (2004) Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 279(6), 4479-89.
Weng, J.R., Tsai, C.H., Kulp, S.K. & Chen, C.S. (2008) Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262(2), 153-63.
Weng, J.R., Tsai, C.H., Kulp, S.K., Wang, D., Lin, C.H., Yang, H.C., Ma, Y., Sargeant, A., Chiu, C.F., Tsai, M.H. & Chen, C.S. (2007) A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res 67(16), 7815-24.
Xia, W., Liu, L.H., Ho, P. & Spector, N.L. (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23(3), 646-53.
Yarden, Y. (2001) Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl 2, 1-13.
Yarden, Y. & Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2), 127-37.
Yoeli-Lerner, M. & Toker, A. (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5(6), 603-5.
Yoo, G.H., Hung, M.C., Lopez-Berestein, G., LaFollette, S., Ensley, J.F., Carey, M., Batson, E., Reynolds, T.C. & Murray, J.L. (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7(5), 1237-45.
Yu, D., Hamada, J., Zhang, H., Nicolson, G.L. & Hung, M.C. (1992) Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7(11), 2263-70.
Yu, D. & Hung, M.C. (2000a) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19(53), 6115-21.
Yu, D. & Hung, M.C. (2000b) Role of erbB2 in breast cancer chemosensitivity. Bioessays 22(7), 673-80.
Yu, D., Suen, T.C., Yan, D.H., Chang, L.S. & Hung, M.C. (1990) Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A 87(12), 4499-503.
Yu, Z., Mahadevan, B., Lohr, C.V., Fischer, K.A., Louderback, M.A., Krueger, S.K., Pereira, C.B., Albershardt, D.J., Baird, W.M., Bailey, G.S. & Williams, D.E. (2006) Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene. Carcinogenesis 27(10), 2116-23.
Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A. & Yoshinaga, S.K. (1996) Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271(7), 3884-90.
Zhang, L., Chang, C.J., Bacus, S.S. & Hung, M.C. (1995) Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 55(17), 3890-6.
Ziober, B.L., Turner, M.A., Palefsky, J.M., Banda, M.J. & Kramer, R.H. (2000) Type I collagen degradation by invasive oral squamous cell carcinoma. Oral Oncol 36(4), 365-72.
行政院衛生署 (2007) 96年主要死因分析. 台北.
李志瑋 (2004) 人類大腸直腸腺癌神經膠原致癌基因-蛋白之相關性及其臨床意義的研究. In 醫學科學研究所, Vol. 博士, p. 180. 國防醫學院.
莊子超 (2002) 神經膠原致癌基因標的癌症基因治療之研究. In 生命科學研究所, Vol. 博士, p. 159. 國防醫學院.
葉明翰 (2003) 錳型超氧歧化酶抑制攝護腺癌細胞中神經膠原致癌基因表現之研究. In 生物化學研究所, Vol. 碩士, p. 66. 國防醫學院.


論文使用權限
  • 同意紙本無償授權給館內讀者為學術之目的重製使用,於2013-08-07公開。
  • 同意授權瀏覽/列印電子全文服務,於2018-04-25起公開。


  • 若您有任何疑問,請與我們聯絡!
    圖書館: 請來電 (02)2621-5656 轉 2281 或 來信